| Detailed information |
|---|
| CancerLivER ID | 2266 |
| Biomarker | AURKB-Sv2 variant |
| Biomarker Name/Symbol (given in Publication) | AURKB-Sv2 variant |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Aberrant expression was associated with the advanced stages of HCC (P < 0.01), correlated with a poor outcome (P = 0.008) and short disease-free period (P = 0.018) and validated on independent dataset |
| Experimental Condition | Metastatic HCC v/s Primary HCC; correlated with a poor outcome and short disease-free period |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in metastatic HCC than primary HCC and Absent in normal |
| Level of significance | p < 0.01 |
| Source | Cell line and Tissue |
| PMID | 19134008 |
| Type of Biomarker | Prognostic |
| Pathway | Aurora B signaling and Metabolism of proteins |
| Cohort | HCC cell lines, PLC/PRF/5, SK-Hep1, HepB3, JHH4, JHH5, HLE, HepG2, Huh1, Huh6, Huh7; 125 HCC cases, of which we found 94 chronic hepatitis and cirrhosis background liver specimens, 18 metastatic liver cancer cases and 16 normal liver; |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Metastatic HCC v/s Primary HCC |
| Year of Publication | 2009 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |